Evidence map›Paper›PMID 35447904›Full record

ArticleMarine drugs2022

Adsorption Characteristics and Enrichment of Emodin from Marine-Derived

Lizhi Gong, Yuzhen Wu, Xiaohan Qiu, Xiujuan Xin, Faliang An, Miaomiao Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lizhi GongKey Laboratory of Cosmetic, China National Light Industry, Beijing Technology and Business University, No. 11/33, Fucheng Road, Beijing 100048, China.
Yuzhen WuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
Xiaohan QiuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
Xiujuan XinState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
Faliang AnState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.ORCID 0000-0002-3011-4741
Miaomiao GuoKey Laboratory of Cosmetic, China National Light Industry, Beijing Technology and Business University, No. 11/33, Fucheng Road, Beijing 100048, China.
East China University of Science and Technology · CNBeijing Technology and Business University · CN

Funding

National Key R&D Program of China 2018YFC1706206National Natural Science Foundation of China 41876189
6 · The paper itself

Abstract

Emodin, a hydroxyanthraquinone derivative, has been used as medicine for more than 2000 years due to its extensive pharmacological activities. Large-scale production of emodin has been achieved by optimizing the fermentation conditions of marine-derived

Indexed as

EmodinAdsorptionAspergillusEthanolPlant ExtractsEmodinEthanolPlant Extractsadsorption kinetics and isothermsAspergillus flavipes HN4-13emodinenrichmentmacroporous resin XAD-16

Identifiers

PMID35447904
PMCPMC9028206
OpenAlexW4221049028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.